PRINCETON, N.J. -- Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60

read more>>

San Diego -- Ambit Biosciences Corporation announced today the presentation of two posters presenting the results of preclinical studies evaluating AC220 at the 51st Annual Meeting of the American Society of Hematology (ASH) in New OrleansAC220, Ambit's lead product candidate, is a novel, orally a

read more>>

LEXINGTON, Mass. -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the results of a study evaluating the activity of elesclomol against acute El

read more>>

Cambridge, UK -- Astex Therapeutics, the UK based biotechnology company developing targeted therapies for oncology, announced today that it is to present important new pre-clinical data on its combinatorial oncogenic kinase inhibitor, AT9283, at the 51st American Society of Hematology (ASH) Annual

read more>>

WHITE PLAINS, N.Y. -- Researchers from around the world will present their findings in blood cancer research at the annual American Society of Hematology (ASH) conference in New Orleans December 4-8, 2009Throughout the ASH conference, The Leukemia & Lymphoma Society (LLS) experts, including Ch

read more>>

Cambridge, UK -- Astex Therapeutics announced today that it has been granted orphan-drug designation by the U.S. Food and Drug Administration for AT9283, its combinatorial oncogenic kinase inhibitor, for the treatment of patients with Acute Myeloid Leukaemia (AML).The Company also confirmed that

read more>>

Long durations of exposure to formaldehyde used for embalming in the funeral industry were associated with an increased risk of death from myeloid leukemia, according to a new study published online November 20 in the Journal of the National Cancer Institute.Previous studies have shown excess morta

read more>>

London -- Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, is pleased to announce that it has signed a collaboration agreement (the “Agreement”) with Pharmasynthez ZAO (“Phar

read more>>

Minneapolis/st. Paul -- A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning.This finding has the potential to chan

read more>>

South San Francisco, Calif. -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML…

read more>>